FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
Source: SeekingAlpha
2025-11-04 08:48:09 ET
Thesis
Read the full article on Seeking Alpha
For further details see:
FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
0.3% G/L:
$16.72 Last:
785,802 Volume:
$16.50 Open:
SRPT Latest News
March 16, 2026 08:33:00 am
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
